Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Rhinitis, Allergic, Perennial, Asthma

In brief

There is currently no effective way to prevent development of allergic rhinitis (nasal allergies) and asthma and no cure. Sublingual immunotherapy (SLIT), a type of therapy in which allergens are placed under the tongue, may be a way to control and possibly prevent allergic rhinitis and asthma. However, detailed research of this approach is limited. The purpose of this study is to evaluate the safety and efficacy of a sublingual cockroach extract given to adults with perennial allergic rhinitis, asthma, or both.

Key facts

Study ID

NCT00829985

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

54

Starts

2009-01-01

Expected to finish

2009-12-01

Last updated by the study team

2017-03-21

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• History of perennial allergic rhinitis, asthma, or both for a minimum of 1 year prior to study entry;
• Positive skin prick test to German cockroach;
• No known contraindications to therapy with glycerinated German cockroach allergenic extract or placebo; and
• Willing to sign the written Informed Consent prior to initiation of any study procedures.

You may not qualify if…

• Cannot perform spirometry at screening;
• Have clinically significant abnormal laboratory values;
• Have an Asthma classification of severe persistent at screening;
• Hospitalized for asthma within the 6 months prior to study entry;
• Life-threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within the 2 years prior to study entry;
• No access to a telephone;
• Received allergen immunotherapy within the last 12 months prior to study entry and plan on initiating or resuming immunotherapy during the study;
• Treatment with anti-immunoglobulin E (anti-IgE) therapy within 1 year of study entry;
• Received an investigational drug within the 30 days prior to study entry and plan on using an investigational drug during the study;
• Experienced nausea, vomiting, abdominal pain or cramps, or diarrhea within the 3 months prior to study entry;
• Refuse to sign the Epinephrine Auto-injector Training Form;
• Does not primarily speak English;
• Plan to move from the area during the study period;
• History of idiopathic anaphylaxis or anaphylaxis grade 3;
• Using tricyclic antidepressants or beta-adrenergic blocker drugs;
• Clinically unacceptable complete blood count (CBC) and liver function tests, as defined by a hemoglobin less than 11.5 in males and 10.0 in females, or platelet counts less than 150,000 and an Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) greater than twice the upper limit of normal;
• Any condition that, in the opinion of the investigator, would interfere with the study; or
• Pregnant or breastfeeding.

Where it is running

• National Jewish Center — Denver, Colorado, United States
• Childrens Memorial Hospital — Chicago, Illinois, United States
• Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
• Boston University School of Medicine — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.